NYSE · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Abbott Laboratories ABT
19 fiscal years on record · USD · FY2025 reported · SEC filings only
3 YEARS OF DIVIDEND GROWTH
In brief
What this company does
Written from the business description in ABBOTT LABORATORIES's annual report to the U.S. Securities and Exchange Commission, filed 20 February 2026. Every sentence was checked against that document before publication.
Growth
USD 44.3B
Revenue, FY2025 · full 19-year series below
Revenue $B
Net income $B
FY2025 · Revenue 44.3 · Net income 6.5
Compound annual growth
+0.5%
+5.1%
+8.1%
+1.6%
−2.0%
+7.7%
+4.0%
−1.6%
+8.3%
+2.5%
+1.5%
+7.7%
+2.1%
−12.7%
+11.2%
+3.2%
+2.4%
3 yrs
5 yrs
10 yrs
15 yrs
Revenue compounded at +5.1% a year over five years — but profit grew faster: net income at +7.7%, earnings per share at +8.3%.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
15 cents
of every revenue dollar became profit
Operating margin
Net margin
FY2025 · Operating 18.2% · Net 14.7%
ROE
FY2025 · ROE 13.1%
Each USD of equity produced 13 cents of profit this year.
The 19-year record
19 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 44.3 | 42.0 | 40.1 | 43.7 | 43.1 | 34.6 | 31.9 | 30.6 | 27.4 | 20.9 | 20.4 | 20.2 | 19.7 | 19.1 | 21.4 | 35.2 | 30.8 | 29.5 | 25.9 |
| Operating income $B | 8.1 | 6.8 | 6.5 | 8.4 | 8.4 | 5.4 | 4.5 | 3.6 | 1.6 | 3.0 | 2.9 | 2.6 | 2.1 | 1.4 | 1.6 | 6.1 | 6.2 | 5.7 | 4.6 |
| EBITDA $B | 9.5 | 8.2 | 7.8 | 9.6 | 9.9 | 6.6 | 5.6 | 4.8 | 2.6 | 3.8 | 3.7 | 3.5 | 3.1 | 2.7 | 3.0 | 7.3 | 7.4 | 6.7 | 5.7 |
| Income tax $B | 1.9 | −6.4 | 0.9 | 1.4 | 1.1 | 0.5 | 0.4 | 0.5 | 1.9 | 0.3 | 0.6 | 0.8 | 0.1 | −0.5 | 0.1 | 1.1 | 1.4 | 1.1 | 0.9 |
| Net income $B | 6.5 | 13.4 | 5.7 | 6.9 | 7.1 | 4.5 | 3.7 | 2.4 | 0.5 | 1.4 | 4.4 | 2.3 | 2.6 | 6.0 | 4.7 | 4.6 | 5.7 | 4.9 | 3.6 |
| Free cash flow $B | 7.4 | 6.4 | 5.1 | 7.8 | 8.6 | 5.7 | 4.5 | 4.9 | 4.4 | 2.1 | 1.9 | 2.6 | 2.2 | 7.5 | 7.5 | 7.7 | 6.2 | 5.7 | 3.5 |
| EPS, diluted $ | 3.72 | 7.64 | 3.26 | 3.91 | 3.94 | 2.50 | 2.06 | 1.33 | 0.27 | 0.94 | 2.92 | 1.49 | 1.62 | 3.72 | 3.01 | 2.96 | 3.69 | 3.12 | 2.31 |
| Dividend / sh $ | 2.40 | 2.24 | 2.08 | 1.92 | · | · | · | · | · | · | · | · | · | · | 1.92 | 1.76 | 1.60 | · | · |
| Payout % | 63 | 29 | 62 | 48 | 45 | 57 | 62 | 83 | 388 | 110 | 33 | 59 | 34 | 53 | 62 | 58 | 42 | 45 | 54 |
| ROE % | 13.1 | 31.1 | 15.2 | 19.1 | 20.6 | 14.1 | 12.0 | 7.7 | 1.9 | 6.7 | 20.7 | 9.8 | 9.9 | 23.3 | 20.1 | 20.2 | 28.3 | 27.7 | 20.3 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 76 reconciliationsAUDITED
Reconciled in 19 of 19 fiscal years.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNYSE
Incorporated inIllinois
Fiscal year endsDecember 31
Data on record since2007